OBJECTIVES: This burden of illness study was conducted to assess the 12-month resource utilization and health care costs, along with the major drivers of those costs, associated with an incident diagnosis of prostate cancer (PC). METHODS: An analysis of incident PC patients identifi ed using a claims database, was performed, for 2005, 2006, and 2007. PC patients and the age and gender matched comparator group (1:4) for each year, were required to have continuous enrollment in a plan and no prostate cancer diagnoses during the 18 months prior to the fi rst diagnosis of prostate cancer in the year. The PC and comparison groups were each described in terms of their health care service use and health care costs, which were compared, using nonparametric Wilcoxon rank-sum tests, with mean values reported here for 2007. RESULTS: There were 21,520 men diagnosed with PC in 2007, in this database, and we selected 86,080 controls. The mean health care cost for the men diagnosed with PC was $19,979 vs. $7,105 for controls; p 0.001. The primary drivers for this nearly triple cost difference between the two groups were: hospitalizations ($6,292 vs. $2,375; p 0.001); radiology tests ($3,014 vs. $348; p 0.001); prescription drugs ($2,293 vs. $1,439; p 0.001); and laboratory tests ($880 vs. $203; p 0.001). Resource utilization over the 12-month period showed that the men with PC, when compared to the control group, had a signifi cantly greater (p 0.001) mean number of hospitalizations (0.4 vs. 0.2; p 0.001); radiology tests (10 vs. 2; p 0.001); prescription drugs (22 vs. 16; p 0.001); and laboratory tests (18 vs. 8; p 0.001). CONCLU-SIONS: The signifi cantly higher 12-month resource utilization and health care costs noted in men diagnosed with PC, compared to age and gender matched controls, are primarily driven by an increased need for hospitalizations, radiology tests, prescription drugs, and laboratory tests. OBJECTIVES: To characterize health care resource use and costs in US women with incident metastatic breast cancer receiving chemotherapy as their principal treatment modality. METHODS: Using a retrospective cohort design and a large private health insurance claims database (2000)(2001)(2002)(2003)(2004)(2005), we identifi ed all women initiating chemotherapy for incident metastatic breast cancer with no evidence of concomitant or subsequent receipt of hormonal therapy or trastuzumab. Health care resource use (inpatient, outpatient, medications) and costs were tallied on a cumulative basis from date of chemotherapy initiation (ie, index date) to date of disenrollment from the health plan (in most instances, presumably due to death) or the end of the study period, whichever occurred fi rst. Study measures were summarized using Kaplan-Meier Sample Average (KMSA) method; 95% CIs were generated using nonparametric bootstrapping. Reimbursed amounts were used as a proxy for costs. RESULTS: The study population consisted of 820 women; mean (SD) age was 58.4 (12.0) years. Over a mean follow-up of 692 days (range: 3 to 2,182), study subjects averaged 1.1 hospital admissions, 6.8 inpatient days, and 62.4 physician offi ce and hospital outpatient visits. Mean (95% CI) cumulative total health care costs were $91,400 ($83,804, $99,050) per patient over this period. Outpatient chemotherapy constituted 24% of total health care costs; comparable percentages for inpatient care, outpatient services, and all other outpatient pharmacotherapy were 19%, 32%, and 24%, respectively. CONCLU-SIONS: Health care costs are high in US women with incident metastatic breast cancer receiving chemotherapy as their principal treatment modality. This study provides important additional information on the cost of treatment of this disease.
PCN58 HEALTH CARE COSTS IN WOMEN WITH INCIDENT METASTATIC BREAST CANCER RECEIVING CHEMOTHERAPY AS THEIR PRINCIPAL TREATMENT MODALITY
Vera-Llonch M 1 , Glass A 2 , Weycker D y 1 , Borker R 3 , Gao S 3 , Oster G 1 1 PAI, Brookline, MA, USA, 2 Kaiser Permanente, Northwest Region, Portland, OR, USA, 3 Amgen, Thousand Oaks, CA, USA OBJECTIVES: To characterize health care resource use and costs in US women with incident metastatic breast cancer receiving chemotherapy as their principal treatment modality. METHODS: Using a retrospective cohort design and a large private health insurance claims database (2000) (2001) (2002) (2003) (2004) (2005) , we identifi ed all women initiating chemotherapy for incident metastatic breast cancer with no evidence of concomitant or subsequent receipt of hormonal therapy or trastuzumab. Health care resource use (inpatient, outpatient, medications) and costs were tallied on a cumulative basis from date of chemotherapy initiation (ie, index date) to date of disenrollment from the health plan (in most instances, presumably due to death) or the end of the study period, whichever occurred fi rst. Study measures were summarized using Kaplan-Meier Sample Average (KMSA) method; 95% CIs were generated using nonparametric bootstrapping. Reimbursed amounts were used as a proxy for costs. RESULTS: The study population consisted of 820 women; mean (SD) age was 58.4 (12.0) years. Over a mean follow-up of 692 days (range: 3 to 2,182), study subjects averaged 1.1 hospital admissions, 6.8 inpatient days, and 62.4 physician offi ce and hospital outpatient visits. Mean (95% CI) cumulative total health care costs were $91,400 ($83,804, $99,050) per patient over this period. Outpatient chemotherapy constituted 24% of total health care costs; comparable percentages for inpatient care, outpatient services, and all other outpatient pharmacotherapy were 19%, 32%, and 24%, respectively. CONCLU-SIONS: Health care costs are high in US women with incident metastatic breast cancer receiving chemotherapy as their principal treatment modality. This study provides important additional information on the cost of treatment of this disease. (SEER 2005) . CONCLUSIONS: The incidence of cervical cancer has decreased in the US in recent years but it still poses a major challenge to the US and developing countries.
PCN59 INCIDENCE RATE AND BURDEN OF ILLNESS OF CERVICAL CANCER IN THE UNITED STATES

PCN60
COSTS OF CARE FOR ELDERLY METASTATIC PROSTATE CANCER PATIENTS OVER TIME
Obeidat NA 1 , Onukwugha E 2 , Bikov K 1 , Seal B 3 , Mullins CD 2 1 University of Maryland, Baltimore, MD, USA, 2 University of Maryland School of Pharmacy, Baltimore, MD, USA, 3 Sanofi -Aventis, Bridgewater, NJ, USA OBJECTIVES: Costs of all-stage prostate cancer management over time have been previously examined and are described as U-shaped. There is less information specifically with regard to late-stage prostate cancer (PC), where patterns of care may differ. The objective of this study is to examine costs of management of regionally metastasized (i.e. M1) PC patterns. METHODS: SEER-Medicare patients (pts) aged 65 and diagnosed with M1 PC between 1994-2002 were selected. The sample was refi ned to pts surviving 18 to 36 months post-diagnosis. Mean monthly service (physician, outpatient facility, hospital, DME, hospice, home health care, and skilled nursing facility (SNF))-specifi c costs were calculated using Medicare payments to providers. Cost patterns at 6 months pre-diagnosis, 6-months post-diagnosis, and 12 months before death were plotted. Graphs were stratifi ed by whether or not patients received treatment for PC (radiation, surgery, drug therapy). RESULTS: A total of 1678 pts were available for the analysis based on the inclusion criteria. Approximately 88% received treatment. A U-shaped cost accrual pattern was observed for treated patients and patients managed by watchful waiting (WW). A peak in costs was observed at month of diagnosis, and a higher peak at time of death. The magnitude of costs was higher among treated patients, with mean costs reaching approximately $7500 at death (versus $4000 among patients under WW). Among cost components, hospital services contributed the most to cost accrual, more so in untreated patients. Treated patients cost more than untreated patients with regards to physician services, while untreated patients appeared to incur SNF costs more consistently across the observation period. CONCLUSIONS: In late-stage prostate cancer, costs of care assume a U-shape, with the highest costs being incurred at diagnosis and at the end of life. Patterns and components of care differed somewhat between treated and untreated patients while hospital services consistently accounted for the most spending.
PCN61 THE ECONOMIC BURDEN OF METASTATIC BREAST CANCER
Foster T 1 , Miller JD J 1 , Boye ME 2 , Blieden MB 1 , Ancukiewicz V 1 , Russell MW 1 1 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: Metastatic breast cancer (MBC) is incurable, but survival and quality of life may be prolonged for years with available therapies; however, costs associated with MBC and its treatment are not fully defi ned. We conducted this research to compile and synthesize the published research concerning the health economics of MBC. METHODS: We systematically reviewed MEDLINE-indexed, Englishlanguage literature, using keyword searches to identify articles published in the 5 years before October 2008. We excluded articles related to supportive therapy, early dis ease, diagnosis, non-economic issues, regions outside North America, Europe or Australia, or economic methods. Additional articles were added from searches of non-MEDLINE-indexed sources such as organization and government websites. RESULTS: Of 43 articles identifi ed from MEDLINE, 19 were included; an additional 13 articles and abstracts were added from non-MEDLINE-indexed sources, for a total of 32 articles and abstracts. No comprehensive study was found which included estimates of the total MBC economic burden across all treatment options. Most (7 of 10) analyses of the per-patient direct MBC costs originate from the US. The only published national MBC costs were derived from UK data. Thirteen economic models have been published showing that numerous treatments are cost-effective, yet generally provide only small improvements in survival. Nine published economic models evaluate hormonal therapies; 7 compare letrozole and tamoxifen and generally show letrozole to be costeffective. In health technology assessments, trastuzumab, capecitabine, and gemcitabine have been judged cost-effective, with inconsistent results for vinorelbine. CONCLU-SIONS: There is no known recent publication concerning the overall economic burden of MBC. However, many publications assess the costs and cost-effectiveness of available treatments. Models show that some of these treatments, most notably letrozole, are cost-effective. More MBC economic evaluations should be published to better inform the use of new treatment modalities in a variety of health care settings.
